The French group Universal Medica Announces its €100,000 2013 Innovation Award
The award is aimed at SMEs and researchers to innovate in preventive and curative therapies, medical devices and technological tools.
By Biocat
Universal Medica Group presents the fifth edition of its Innovation Award 2013, also known as Universal Biotech Innovation Prize. The award of €100,000, aimed at small and medium enterprises and academic researchers, aims to support new talent and innovative processes and products in the field of biotechnology, especially in preventive and curative therapies, medical devices and technological tools.
This year's jury is made up of experts from both public and private sectors, including the Pasteur Institute, the Ministry of Higher Education and Research of France, the European Commission, the National Agency French Research (ANR), GlaxoSmithKline, Sanofi Pasteur and AstraZeneca.
All candidates will participate in the event Innovation Days 2013, organized by Universal Medica, next 7th to 9th October 2013 in Paris (France). The aim of this event, in addition to naming the winners at the final ceremony, is to encourage networking with international actors in the field of life sciences. Therefore, candidates for the award will enhance their visibility through the display of posters and will have the opportunity to make contacts with other companies and research institutions.
The registration period is from 4 to 15 April 2013.
Last year edition, 81 projects were submitted from 16 European countries. In Catalonia there were four finalists. The Swedish company Immune Therapy Holdings won for developing a personalized treatment for inflammatory diseases or immunomediades.
Questions: prix-innovation@universal-biotech.com
Related news about the 2012 edition (12 September 2012)